Carmat

Carmat FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of Carmat (ALCAR.PA) as of Oct 26, 2026 is 87.20 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 108.61 % — a change of -19.71% (lower).

FCF Conversion

87.20 %

YoY

-19.71%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Carmat is 2024 87.20 % . FCF Conversion Rate (FCF/EBITDA) of Carmat was 2023 108.61 % . It decreases by -19.71% lower compared to the previous year.

The Carmat FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
95.14 EUR
Jan 1, 2018
96.70 EUR
Jan 1, 2019
95.89 EUR
Jan 1, 2020
122.71 EUR
Jan 1, 2021
100.10 EUR
Jan 1, 2022
105.00 EUR
Jan 1, 2023
108.61 EUR
Jan 1, 2024
87.20 EUR
The Carmat FCF Conversion history
YEARFCF ConversionYoY
87.20 %-19.71%
108.61 %+3.43%
105.00 %+4.90%
100.10 %-18.43%
122.71 %+27.98%
95.89 %-0.84%
96.70 %+1.64%
95.14 %+1.71%
93.54 %-5.72%
99.22 %-4.01%
103.36 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Carmat Stock analysis

What does Carmat do? Carmat SA is a French company that was founded in 2008 and is headquartered in Vélizy-Villacoublay, France. The company is involved in the development, manufacture, and sale of cardiovascular systems and artificial hearts. Carmat is a leader in developing technologies for the treatment of serious heart conditions and aims to provide highly innovative solutions for patients suffering from end-stage heart failure. The business model of Carmat is based on the development and commercialization of products that contribute to improving the quality of life for patients with serious heart conditions. The artificial hearts are made from biocompatible materials and can be implanted in human bodies. They can serve as a bridge to a heart transplant or even as a permanent solution for complete replacement of the natural heart. Carmat is divided into various divisions including research and development, production, sales, and marketing. The company's research and development department works on developing highly specialized technologies for the artificial hearts to enhance performance and reliability. The production department manufactures the artificial hearts and ensures a strictly controlled, sterile environment to ensure the highest quality of products. The sales and marketing team ensures that the artificial hearts are marketed and sold worldwide. Carmat currently offers the Carmat heart, which is considered a revolutionary product in the market. The heart is made from biocompatible materials and is produced through a strictly controlled process. It has been designed to maximize performance and reliability in an artificial heart solution. The artificial hearts are implanted in an elaborate and fully equipped operating room to ensure an optimal environment. Carmat has also formed partnerships with other companies and institutions to strengthen its research and development department and share knowledge and experience in the industry. This includes a partnership with Airbus, which supports the company in developing new technologies. Carmat also collaborates with medical facilities to test the artificial hearts and improve their performance. Overall, Carmat is a leading brand in the field of artificial hearts. The company aims to develop innovative products to improve the lives of people with heart failure. It has established itself as a reliable provider of artificial hearts in the market and strives to constantly improve its business activities to meet the growing demand for more effective treatment options for patients with heart problems. Carmat is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Carmat stock

FCF Conversion Rate (FCF/EBITDA) of Carmat is 87.20 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of Carmat changed from 108.61 % to 87.20 %, representing a -19.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Carmat since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Carmat with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Carmat

All Key Metrics — Carmat